Phico Therapeutics
UK biotechnology company focused on anti-infective therapeutics and a therapeutic delivery platform advanced from concept into a Phase I clinical trial. The organisation demonstrates microbiology-led R&D, early-phase clinical development capabilities, experience securing public R&D funding, and engagement with advisors who have investment, corporate transaction and life-science leadership experience.
Industries
Nr. of Employees
small (1-50)
Phico Therapeutics
Cambridge, Cambridgeshire, United Kingdom, Europe
Patents
Anti-bacterial compositions comparing lytic modified bacteriophage engineered to infect and kill different target bacteria
US-11732243-B2
View Details
Anti-bacterial compositions comparing lytic modified bacteriophage engineered to infect and kill different target bacteria
US-11732243-B2
View DetailsProducts
Proprietary therapeutic delivery platform (early-stage)
A company-developed therapeutic delivery platform advanced through preclinical development and a Phase I clinical study.
Proprietary therapeutic delivery platform (early-stage)
A company-developed therapeutic delivery platform advanced through preclinical development and a Phase I clinical study.
Services
Research and development services focused on anti-infective therapeutics and advancing candidates through preclinical studies into early clinical trials.
Research and development services focused on anti-infective therapeutics and advancing candidates through preclinical studies into early clinical trials.
Expertise Areas
- Anti-infective drug development
- Therapeutic delivery platform development
- Early-phase clinical development (Phase I)
- Microbiology and infectious disease research
Key Technologies
- Therapeutic delivery platforms (early-stage)
- Clinical trial conduct (Phase I)
- Microbiological assays and testing
- Preclinical translational workflows
News & Updates
Announcement of Innovate UK award to support company R&D activities.
Multiple press releases and media appearances describing company appointments, funding and programme progress.
Press coverage mentioning company context and investor interest in anti-infective initiatives.
Company-developed therapeutic delivery platform progressed from concept to a Phase I clinical study.
Announcement of Innovate UK award to support company R&D activities.
Multiple press releases and media appearances describing company appointments, funding and programme progress.
Press coverage mentioning company context and investor interest in anti-infective initiatives.
Company-developed therapeutic delivery platform progressed from concept to a Phase I clinical study.